Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunogenicity of a third dose with mRNA-vaccines in the ChAdOx1-S/BNT162b2 vaccination regimen against SARS-CoV-2 variants.
García-Pérez J, Borobia AM, Pérez-Olmeda M, Portolés A, Castaño L, Campins-Artí M, Bertrán MJ, Bermejo M, Arribas JR, López A, Ascaso-Del-Rio A, Arana-Arri E, Fuentes Camps I, Vilella A, Cascajero A, García-Morales MT, Castillo de la Osa M, Pérez Ingidua C, Lora D, Jiménez-Santana P, Pino-Rosa S, Gómez de la Cámara A, De La Torre-Tarazona E, Calonge E, Cruces R, Belda-Iniesta C, Alcamí J, Frías J, Carcas AJ, Díez-Fuertes F; CombiVacS Study Group. García-Pérez J, et al. Among authors: portoles a. iScience. 2024 Aug 14;27(9):110728. doi: 10.1016/j.isci.2024.110728. eCollection 2024 Sep 20. iScience. 2024. PMID: 39286494 Free PMC article.
Economic impact of immunoglobulin replacement therapy in secondary immunodeficiency to hematological cancer: a single center observational study.
Guerola LDC, Sacristán AAG, Portolés A, Jasso M, Guerra-Galán T, de la Fuente-Munoz E, Palacios-Ortega M, Fernández-Arquero M, Cuesta-Mínguez C, Rodríguez-Sanz A, Peña-Cortijo A, Polo M, Morales MM, Anguita-Mandly E, Benítez Jiménez T, Benavente Cuesta C, Sánchez-Ramón S. Guerola LDC, et al. Among authors: portoles a. Front Immunol. 2024 Jun 26;15:1413231. doi: 10.3389/fimmu.2024.1413231. eCollection 2024. Front Immunol. 2024. PMID: 38989286 Free PMC article.
Amantadine and/or transcranial magnetic stimulation for fatigue associated with multiple sclerosis (FETEM): study protocol for a phase 3 randomised, double-blind, cross-over, controlled clinical trial.
Matias-Guiu JA, González-Rosa J, Hernández MÁ, Martínez-Ginés ML, Portolés A, Pérez-Macías N, Benito-León J, Padrón I, Prieto J, Matias-Guiu J. Matias-Guiu JA, et al. Among authors: portoles a. BMJ Open. 2024 Jan 4;14(1):e078661. doi: 10.1136/bmjopen-2023-078661. BMJ Open. 2024. PMID: 38176857 Free PMC article.
Academia and industry agreement on a feasibility tool for first-time-in-human clinical trial units.
Moraga P, Prieto P, Conradie A, Benhayoun M, Rousell V, Davy M, Fuhr U, Antonijoan Arbos R, Abad-Santos F, Portolés A, Van Duinen J, Carcas AJ, Borobia AM; ERA4TB Consortium. Moraga P, et al. Among authors: portoles a. Clin Transl Sci. 2023 Dec;16(12):2421-2428. doi: 10.1111/cts.13655. Epub 2023 Oct 11. Clin Transl Sci. 2023. PMID: 37818923 Free PMC article.
Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study.
García-Pérez J, González-Pérez M, Castillo de la Osa M, Borobia AM, Castaño L, Bertrán MJ, Campins M, Portolés A, Lora D, Bermejo M, Conde P, Hernández-Gutierrez L, Carcas A, Arana-Arri E, Tortajada M, Fuentes I, Ascaso A, García-Morales MT, Erick de la Torre-Tarazona H, Arribas JR, Imaz-Ayo N, Mellado-Pau E, Agustí A, Pérez-Ingidua C, Gómez de la Cámara A, Ochando J, Belda-Iniesta C, Frías J, Alcamí J, Pérez-Olmeda M; CombiVacS study Group. García-Pérez J, et al. Among authors: portoles a. EClinicalMedicine. 2022 Jul 1;50:101529. doi: 10.1016/j.eclinm.2022.101529. eCollection 2022 Aug. EClinicalMedicine. 2022. PMID: 35795713 Free PMC article.
Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study.
Ascaso-Del-Rio A, García-Pérez J, Pérez-Olmeda M, Arana-Arri E, Vergara I, Pérez-Ingidua C, Bermejo M, Castillo de la Osa M, Imaz-Ayo N, Riaño Fernández I, Astasio González O, Díez-Fuertes F, Meijide S, Arrizabalaga J, Hernández Gutiérrez L, de la Torre-Tarazona HE, Mariano Lázaro A, Vargas-Castrillón E, Alcamí J, Portolés A; RescueVac study Group. Ascaso-Del-Rio A, et al. Among authors: portoles a. EClinicalMedicine. 2022 Jul 1;51:101542. doi: 10.1016/j.eclinm.2022.101542. eCollection 2022 Sep. EClinicalMedicine. 2022. PMID: 35795398 Free PMC article.
Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT).
Rossello X, Raposeiras-Roubin S, Latini R, Dominguez-Rodriguez A, Barrabés JA, Sánchez PL, Anguita M, Fernández-Vázquez F, Pascual-Figal D, De la Torre Hernandez JM, Ferraro S, Vetrano A, Pérez-Rivera JA, Prada-Delgado O, Escalera N, Staszewsky L, Pizarro G, Agüero J, Pocock S, Ottani F, Fuster V, Ibáñez B; REBOOT-CNIC investigators. Rossello X, et al. Eur Heart J Cardiovasc Pharmacother. 2022 May 5;8(3):291-301. doi: 10.1093/ehjcvp/pvab060. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 34351426 Clinical Trial.
130 results